Narrowband UVB Treatment in Patients With Vitiligo

Mary Sullivan-Whalen

Status: Completed

Conditions: Vitiligo

Treatments: Device: Narrowband UVB

Study type: Interventional

Funder types: Other

Identifiers

NCT00398723

RUH IRB # JCO 0590

Details and patient eligibility

About

The study offers narrowband UVB light therapy to patients who have 5% of their body involved with vitiligo.

The hypothesis is that Narrowband UVB promotes melanocyte proliferation in vitiligo lesions.

Full description

All patients will receive phototherapy, with narrowband UVB, three times a week for six months, or a total of 78 treatments. 6mm punch skin biopsies (2) will be done prior to starting therapy, once during treatment (2) and at the completion of the study (2). Clinical assessments and photography will be done parallel to the skin biopsies. Results (clinically and histologically) will be analyzed.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years of age or greater
• Vitiligo with extensive skin involvement (>5% body surface affected).

Exclusion criteria

• No treatment with topical steroids, calcineurin inhibitors or vitamin D analogs for at least 4 weeks prior to entering the study.
• No treatment with systemic therapies, including methotrexate, etretinate, PUVA, or cyclosporine 4 weeks prior to entering the study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Vitiligo

Experimental group

Description:

adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB

Treatment:

Device: Narrowband UVB